Search Patents
  • Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof
    Publication number: 20220177982
    Abstract: Methods of treating subjects having a coronavirus infection, and methods of identifying subjects having an increased risk of a coronavirus infection are provided herein.
    Type: Application
    Filed: December 3, 2021
    Publication date: June 9, 2022
    Inventors: Jack Kosmicki, Julie Horowitz, Manuel Allen Revez Ferreira, Goncalo Abecasis, Aris Baras, Amy Damask
  • METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION
    Publication number: 20240016813
    Abstract: The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering an angiontensin converting enzyme-2 (ACE2) modulator.
    Type: Application
    Filed: September 9, 2021
    Publication date: January 18, 2024
    Inventors: Kevin Brown, Kevin Brogle
  • MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOF
    Publication number: 20230058162
    Abstract: This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing human coronavirus disease, e.g., coronavirus disease 2019 (COVID-19).
    Type: Application
    Filed: July 27, 2021
    Publication date: February 23, 2023
    Inventors: Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
  • Magnetic Resonance System and Method for Weakening and Expelling Living Coronavirus from a Patient Body
    Publication number: 20230271023
    Abstract: The present invention relates to a novel COVID-19 treatment system and associated method. The system features an electromagnetic field pulse generator for generating a low frequency electromagnetic field pulse configured to create a magnetic resonance with the magnetic field generated by the living coronavirus in and around a patient body of an infected person. The magnetic resonance weakens the coronavirus and expels the coronavirus from the patient body to an outside chamber wherein the chamber air is sanitized by passing through a disinfectant solution. In some embodiments, the electromagnetic field generated by the generator may include frequencies from radio frequencies to higher millimeter waves to microwaves.
    Type: Application
    Filed: January 10, 2023
    Publication date: August 31, 2023
    Inventor: Svyatoslav Orlov-Kurylov
  • PEPTIDES HAVING PROTEASE ACTIVITY FOR USE IN THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION
    Publication number: 20200353060
    Abstract: The present invention provides a polypeptide having protease activity for use in the treatment or prevention of coronavirus infection in a mammal. In particular, the invention relates to treatment or prevention of a coronavirus infection in a human, using trypsins.
    Type: Application
    Filed: January 7, 2019
    Publication date: November 12, 2020
    Inventors: Ágústa GUDMUNDSDÓTTIR, Bjarki STEFÁNSSON, Gunnar Birgir SANDHOLT
  • Canine respiratory coronavirus (CRCV) spike protein, polymerase and hemagglutinin/esterase
    Patent number: 7776340
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 17, 2010
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING FIBROSIS RESULTING FROM A CORONAVIRUS INFECTION
    Publication number: 20230107479
    Abstract: The invention provides methods, compositions, and kits using a galectin-3 inhibitor to prevent and treat fibrosis resulting from a coronavirus infection, such as fibrosis in a subject's lung resulting from a coronavirus 2 infection.
    Type: Application
    Filed: March 23, 2021
    Publication date: April 6, 2023
    Inventor: Pieter MUNTENDAM
  • MODIFIED S2 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN
    Publication number: 20220213148
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 865. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Annika KRAEMER-KUEHL, Thomas Min Stephan
  • Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases
    Patent number: 11752133
    Abstract: The invention belongs to the technical field of medicine, and particularly relates to use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases. Through the research in the invention, it is found that the bromophenol-pyrazoline compounds inhibit replication of porcine coronaviruses at a cellular level, and can treat porcine coronavirus diseases (such as PEDV and TGEV) in clinical trials, greatly improving the survival rate of infected piglets, so the compounds can be used to prepare drugs for treating porcine coronavirus diseases.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: September 12, 2023
    Assignee: SHANDONG LINGHAI BIOTECHNOLOGY CO., LTD.
    Inventors: Dayong Shi, Xiangqian Li, Xin Wang, Jinbo Yang, Feng Xu, Rong Zhang
  • PANDEMIC-PREPAREDNESS COCKTAIL TO FIGHT CORONAVIRUS OUTBREAKS
    Publication number: 20230242625
    Abstract: Disclosed are novel targets for coronavirus therapies and methods of their use in screens for novel inhibitors of coronaviral infections. Also disclosed are novel coronavirus inhibitors that interact with said targets.
    Type: Application
    Filed: June 11, 2021
    Publication date: August 3, 2023
    Inventors: Deborah F. KELLY, Michael A. CASASANTA, Mariah L. SCHROEN, G.M. JONAID
  • CORONAVIRUS VACCINES AND USES THEREOF
    Publication number: 20230015616
    Abstract: This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
    Type: Application
    Filed: November 30, 2020
    Publication date: January 19, 2023
    Inventors: Bill Biliang ZHANG, Man LI, Lin MA, Jian WEN, Hong ZHANG, Huiling ZHONG
  • Recombinant Human CC10 Protein for Treatment of Influenza, Ebola and Coronavirus
    Publication number: 20230241163
    Abstract: Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin and secretoglobin 1A1 (SCGB1A1), to reduce virus titers in the tissues of patients, particularly influenza, ebola, and coronavirus titers in lung tissues are provided. RhCC10 may be used as a therapeutic in the treatment, cure, or prevention of viral infection, particularly influenza, ebola, and coronavirus infection. More particularly, methods, including broadly the critical dosage ranges of rhCC10, intravenous and intranasal route of administration, which may be administered to treat, cure or prevent influenza, ebola, and coronavirus infection are provided. Further provided are compositions useful in the foregoing methods and in administering rhCC10 to humans.
    Type: Application
    Filed: June 2, 2021
    Publication date: August 3, 2023
    Inventor: Aprile L. PILON-CLAYTON
  • Anti-coronavirus vaccine
    Publication number: 20050053622
    Abstract: The invention relates to a vaccine against coronavirus infections and, in particular, against feline infectious peritonitis (FIP). The inventive vaccine comprises immunogenic peptides included in the S protein of feline coronaviruses (FcoV), which do not result from immunologic enhancement. The invention also relates to the use of at least one peptide for the preparation of a vaccine that induces protection against coronavirus infections, said peptide being selected from the group comprising fragments of an S protein of coronavirus of at least 12 amino acids, included in the SEQ ID NO: 5, or nucleic acid fragments of at least 36 nucleotides, included in the SEQ ID NO: 10 and coding for one of said peptides.
    Type: Application
    Filed: August 9, 2002
    Publication date: March 10, 2005
    Inventors: Andre Aubert, Veronique Duquesne, Marc Eloit, Valerie Gonon
  • BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS
    Publication number: 20170313685
    Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Applicant: Purdue Research Foundation
    Inventors: Sarah Emma St. John, Andrew D. Mesecar
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAVIRUS INFECTIONS
    Publication number: 20240123029
    Abstract: The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-COV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-COV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).
    Type: Application
    Filed: February 8, 2022
    Publication date: April 18, 2024
    Inventors: Alberto MANTOVANI, Cecilia GARLANDA, Barbara BOTTAZZI, Elisa VICENZI
  • METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
    Publication number: 20220246242
    Abstract: The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.
    Type: Application
    Filed: February 8, 2022
    Publication date: August 4, 2022
    Applicant: GENETIC TECHNOLOGIES LIMITED
    Inventors: Gillian Sue Dite, Nicholas Mark Murphy, Richard Allman
  • Broad-spectrum non-covalent coronavirus protease inhibitors
    Patent number: 9975885
    Abstract: This invention pertains to materials and methods for the treatment of patients with coronavirus infection and the control of zoonotic disease outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 22, 2018
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Sarah Emma St. John, Andrew D. Mesecar
  • STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION
    Publication number: 20230192786
    Abstract: The subject invention pertains to the use of STAT3 inhibitors for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering one or more STAT3 inhibitors, such as GLG-305 or GLG-805, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject and, optionally, one or more RNA kinase inhibitors, one or more IL-6 inhibitors and/or one or more Janus kinases (JAK) inhibitors. The subject invention further pertains to pharmaceutical compositions, packaged dosage formulations, and kits for treating or preventing human coronavirus infection.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 22, 2023
    Inventors: RICHARD GABRIEL, HECTOR J. GOMEZ
  • THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION
    Publication number: 20240189305
    Abstract: The present invention makes it possible to treat a coronavirus infection by administering a pharmaceutical composition containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof as an active ingredient to a patient infected with the coronavirus who has an aggravating risk factor and is in an early stage of the disease.
    Type: Application
    Filed: March 30, 2022
    Publication date: June 13, 2024
    Applicant: FUJIFILM TOYAMA CHEMICAL CO., LTD.
    Inventors: Tsutomu SAKURAI, Takahiro YAMATAKE
  • Compositions and methods for prevention and treatment of coronavirus and related disorders
    Patent number: 11938104
    Abstract: Presented herein are compositions and methods for preventing, reducing, delaying and treating a coronavirus infection and related disorders such as respiratory distress, disseminated intravascular coagulation, and central nervous system pathologies caused by coronavirus infection.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: March 26, 2024
    Assignee: ABREXA PHARMACEUTICALS, INC.
    Inventors: Jesus E. Villafranca, Charles Richard Kissinger
Narrow Results

Filter by US Classification